Chronic Inflammatory Demyelinating Polyneuropathy

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

A subpopulation analysis of the phase 2 ADHERE trial suggests clinical benefit and a favorable safety profile for efgartigimod PH20 in Chinese patients with chronic inflammatory demyelinating polyneuropathy.

An international real-world analysis highlighted prolonged time to diagnosis and common misdiagnoses in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

In a plain language summary of the ADHERE trial, subcutaneous efgartigimod improved disability and reduced relapse risk by 61% in CIDP, with sustained benefit and a favorable safety profile.

A randomized trial in patients with CIDP found that adding intravenous methylprednisolone to IVIg did not significantly increase remission rates and was associated with thromboembolic safety concerns.

Grip strength offers neurologists a responsive, objective measure that captures treatment effects and real-world fluctuations—complementing disability scales and helping to guide decision-making in clinical practice.

A perspective model aimed noted that introducing efgartigimod alfa for patients with chronic inflammatory demyelinating polyneuropathy incurs more expected costs.

An analysis of the first 110 patients screened for the ARISE study showed that an independent adjudication committee confirmed the diagnosis of CIDP in nearly 3-quarters of cases.

The FDA-cleared devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more.

Efgartigimod alfa SC is approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

A recent matched cohort analysis revealed that patients with CIDP treated with immunoglobulin had lower rates of assistive device deterioration and opioid use compared with those untreated.

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.

The prefilled syringe is approved for a 20- to 30-second subcutaneous injection, and patients can self-inject following proper instruction in the subcutaneous injection technique.

The company recently announced positive topline results from its phase 3 study in patients with MG and initial data from its phase 2b study in patients with CIDP, both assessing batoclimab.

A minor difference in relapse rates at month 8 between rituximab and placebo narrowed by month 12, indicating no long-term treatment advantage.

In a recent case report, a 46-year-old man living with chronic inflammatory demyelinating polyneuropathy experienced multiple relapses despite various conventional treatments; however, found promise in ofatumumab, an approved drug for multiple sclerosis.

A new study identified key clinical and ultrasound markers that improved the differentiation between 2 conditions with overlapping features.

Early initiation of combined low‐dose rituximab therapy showed better improvements of chronic inflammatory demyelinating polyradiculoneuropathy in a short‐term than delayed initiation.

Previously, Argenx's efgartigimod alfa and hyaluronidase-qvfc was granted orphan drug designation for the treatment of chronic inflammatory demyelinating polyneuropathy in Japan.

A new study highlighted the importance of initiating immunotherapy promptly in chronic inflammatory demyelinating polyneuropathy to prevent axonal damage and disability progression.

A study highlighted corneal confocal microscopy as a promising noninvasive tool for tracking sensory nerve damage in chronic inflammatory demyelinating polyradiculoneuropathy.

Early treatment of CIDP, within 1-year of onset, is associated with better long-term outcomes, highlighting key prognostic factors and treatment timing.

The complement system is critical in immune defense and tissue homeostasis, but its dysregulation can contribute to autoimmune neurological disorders and neurodegenerative diseases like Alzheimer, ALS, and multiple sclerosis.

Human studies revealed thinner myelin sheaths in CD59-deficient patients, indicative of a process of segmental demyelination followed by remyelination.

Delaying treatment past 12 months worsens leg disability scores and leads to a more challenging disease course in CIDP patients.